How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients

by Xiaofu Zhu, Susan Dent, Lise Paquet, Tinghua Zhang, Daniel Tesolin, Nadine Graham, Olexiy Aseyev, Xinni Song
Published 2021-02-01

Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy

by Kevin Emery Boczar, Olexiy Aseyev, Jeffrey Sulpher, Christopher Johnson, Ian G Burwash, Michele Turek, Susan Dent, Girish Dwivedi
Published 2016-08-01

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

by Megan M. Tu, Mark Clemons, Carol Stober, Ahwon Jeong, Lisa Vandermeer, Mihaela Mates, Phillip Blanchette, Anil Abraham Joy, Olexiy Aseyev, Gregory Pond, Dean Fergusson, Terry L. Ng, Kednapa Thavorn
Published 2021-05-01

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

by Mark Clemons, Michelle Liu, Carol Stober, Gregory Pond, Mashari Jemaan Alzahrani, Michael Ong, Scott Ernst, Christopher Booth, Mihaela Mates, Anil Abraham Joy, Olexiy Aseyev, Phillip Blanchette, Lisa Vandermeer, Megan Tu, Kednapa Thavorn, Dean Fergusson
Published 2021-10-01